Clinical Outcomes of Patient Subgroups in the TANGO II Study
Sign Up to like & getrecommendations! Published in 2021 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-021-00405-x
Abstract: Meropenem–vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited applicability to… read more here.
Keywords: renal failure; failure immunocompromised; immunocompromised status; tango study ... See more keywords